Increased levels of circulating interleukin 6, interleukin 8, c-reactive protein, and risk of lung cancer

Journal of the National Cancer Institute

Volumn 103, Issue 14, 2011, Pages 1112-1122

  Pine, Sharon R ^a,b   Mechanic, Leah E ^a,c   Enewold, Lindsey ^d,e   Chaturvedi, Anil K ^a,f   Katki, Hormuzd A ^g   Zheng, Yun Ling ^h   Bowman, Elise D ^a   Engels, Eric A ^a,f   Caporaso, Neil E ^g   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Epidemiology and Genetics Research Program   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Infections and Immunoepidemiology Branch   (United States)

^g Department of Biostatistics Branch ^*  (United States)

^h GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8;

AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SMOKING;

ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79960715096     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr216     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Boyle P, Levin B. World Cancer Report 2008. Lyon, France: IARC Sci Publ; 2008.
3. Manser RL, Irving LB, Stone C, et al. Screening for lung cancer. Cochrane Database Syst Rev. 2004;1:CD001991.
4. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217-2224.
5. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28:2719-2726.
6. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61:824-833.
7. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-2418. (Pubitemid 41437845)
8. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24:5216-5222. (Pubitemid 46631365)
9. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006;15(2):381-384. (Pubitemid 43348407)
10. Davalos AR, Coppe JP, Campisi J, et al. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010;29(2):273-283.
11. Seike M, Yanaihara N, Bowman ED, et al. A cytokine gene signature of the lung adenocarcinoma and its tissue environment predicts prognosis. J Natl Cancer Inst. 2007;99(16):1257-1269. (Pubitemid 47299904)
12. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA. 2001;98(17):9824-9829. (Pubitemid 32769388)
13. Kaminska J, Kowalska M, Kotowicz B, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology. 2006;70(2):115-125. (Pubitemid 43760337)
14. Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002;22(11):1129-1135. (Pubitemid 36051185)
15. Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71(5):1095-1098.
16. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22(10):1668-1673.
17. Kluft C, Leuven JA, Helmerhorst FM, et al. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002;39(3):149-154. (Pubitemid 36398240)
18. Takizawa H, Tanaka M, Takami K, et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol. 2000;278(5):L906-L913. (Pubitemid 30351045)
19. Zheng YL, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis. 2003;24:269-274. (Pubitemid 36267096)
20. Zheng YL, Loffredo CA, Alberg AJ, et al. Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res. 2005;65(20):9566-9573. (Pubitemid 41508027)
21. Olivo-Marston SE, Mechanic LE, Mollerup S, et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis. 2010;31(10):1778-1786.
22. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 suppl):273S-309S.
23. Stowe RP, Peek MK, Cutchin MP, et al. Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A Biol Sci Med Sci. 2010;65:429-433.
24. Enewold L, Mechanic LE, Bowman ED, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009;18(1):215-222.
25. Wojciechowska-Lacka A, Matecka-Nowak M, Adamiak E, et al. Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma. 1996;43(3):155-158. (Pubitemid 26229349)
26. Greene FL, Page DL, Fleming ID, et al., eds.; American Joint Committee on Cancer (AJCC). Cancer Staging Handbook. 6th ed. New York, NY: Springer; 2002.
27. Katki HA, Mark SD. Survival analysis for cohorts with missing covariate information. R News. 2008;8:14-19.
28. Mark SD, Katki HA. Specifying and implementing nonparametric and semiparametric survival estimators in two-stage (sampled) cohort studies with missing case data. J Am Stat Assoc. 2006;101:460-471. (Pubitemid 43972290)
29. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. (Pubitemid 36019639)
30. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605-615. (Pubitemid 351818355)
31. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373-2380. (Pubitemid 350022405)
32. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175-1183. (Pubitemid 46718402)
33. Kamohara H, Ogawa M, Ishiko T, et al. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int J Oncol. 2007;30(4):977-983.
34. Takamori H, Oades ZG, Hoch OC, et al. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas. 2000;21(1):52-56. (Pubitemid 30421934)
35. Lang K, Niggemann B, Zanker KS, et al. Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer. 2002;99(5):673-680. (Pubitemid 34538746)
36. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135-1142.
37. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133(6):1019-1031. (Pubitemid 351787746)
38. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223-1231.
39. Mojtahedi Z, Khademi B, Hashemi SB, et al. Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res. 2011;76(3):7-10.
40. Smith PC, Hobisch A, Lin DL, et al. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12(1):33-40. (Pubitemid 32294585)
41. Mouawad R, Rixe O, Meric JB, et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther. 2002;7(4):151-156. (Pubitemid 37531603)
42. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763- 1771. (Pubitemid 44631359)